Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INvestigation of the Gut microbiomE on STatin Response (INGEST)

Trial Profile

INvestigation of the Gut microbiomE on STatin Response (INGEST)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
  • Focus Pharmacodynamics
  • Acronyms INGEST

Most Recent Events

  • 08 Apr 2025 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.
  • 24 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Mar 2025.
  • 24 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top